Active substance
Ezetimibe
- SFDA 7
- US FDA 17
- Health Canada 18
- US price lines 2
- NHS prices 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EZECHOL 10 mg tablet | 10 mg | Tablet · Oral use | 30 Blister | SAR 131.65 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| EZENTIA | 10 mg | Tablet · Oral use | 30 Blister | SAR 109.50 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| EZETROL 10 mg tablet | 10 mg | Tablet · Oral use | 28 Blister | SAR 159.80 | NCE · Prescription | Organon Pharma UK Limited | Valid |
| Etimicol 10 | 10 mg | Tablet · Oral use | 30 Blister | SAR 118.50 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| LIPIZET 10MG TABLET | 10 mg | Tablet · Oral use | 28 Blister | SAR 110.60 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| ZETEX 10 mg tablet | 10 mg | Tablet · Oral use | 30 Blister | SAR 146.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Zavoxa | 10 mg | Tablet · Oral use | 30 Blister | SAR 118.50 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
Indications — CHI Daman Drug Formulary
CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ISCHEMIC STROKE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZETIA | 10MG | tablet · oral | ORGANON | Prescription | 25 Oct 2002 |
| EZETIMIBE | 10MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 26 Jun 2015 |
| EZETIMIBE | 10MG | tablet · oral | SANDOZ | Prescription | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | ZYDUS PHARMS | Prescription | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | OHM LABS INC | Prescription | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | AMNEAL PHARMS CO | Prescription | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | AUROBINDO PHARMA | Prescription | 25 Aug 2017 |
| EZETIMIBE | 10MG | tablet · oral | ALKEM LABS LTD | Prescription | 21 Dec 2017 |
| EZETIMIBE | 10MG | tablet · oral | ACCORD HLTHCARE | Prescription | 26 Oct 2018 |
| EZETIMIBE | 10MG | tablet · oral | SCIEGEN PHARMS | Prescription | 23 Oct 2020 |
| EZETIMIBE | 10MG | tablet · oral | HETERO LABS LTD III | Prescription | 26 Jul 2022 |
| EZETIMIBE | 10MG | tablet · oral | ORIENT PHARMA | Prescription | 13 Sep 2022 |
| EZETIMIBE | 10MG | tablet · oral | TEVA PHARMS USA | Discontinued | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | WATSON LABS INC | Discontinued | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | APOTEX | Discontinued | 12 Jun 2017 |
| EZETIMIBE | 10MG | tablet · oral | RISING | Discontinued | 26 Apr 2019 |
| EZETIMIBE | 10MG | tablet · oral | MACLEODS PHARMS | Discontinued | 29 Apr 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-EZETIMIBE | 02425610 | 10 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| AG-EZETIMIBE | 02475898 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-EZETIMIBE | 02427826 | 10 MG | TABLET · ORAL | APOTEX INC |
| AURO-EZETIMIBE | 02469286 | 10 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-EZETIMIBE | 02425211 | 10 MG | TABLET · ORAL | BIOMED PHARMA |
| EZETIMIBE | 02422549 | 10 MG | TABLET · ORAL | PRO DOC LIMITEE |
| EZETIMIBE | 02431300 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| EZETIMIBE | 02478544 | 10 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| EZETROL | 02247521 | 10 MG | TABLET · ORAL | ORGANON CANADA INC. |
| JAMP-EZETIMIBE | 02423235 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-EZETIMIBE | 02467437 | 10 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MAR-EZETIMIBE | 02422662 | 10 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MINT-EZETIMIBE | 02423243 | 10 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NRA-EZETIMIBE TABLETS | 02536420 | 10 MG | TABLET · ORAL | NORA PHARMA INC |
| PMS-EZETIMIBE | 02416409 | 10 MG | TABLET · ORAL | PHARMASCIENCE INC |
| SANDOZ EZETIMIBE | 02416778 | 10 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SPC-EZETIMIBE | 02419548 | 10 MG | TABLET · ORAL | SUN PHARMA CANADA INC |
| TEVA-EZETIMIBE | 02354101 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EZETIMIBE 10 MG TABLET | $0.06672 | per EA | 23 Sep 2026 |
| US NADAC | ZETIA 10 MG TABLET | $13.93688 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ezetimibe 10mg tablets | £1.18 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 9 Jan 2026 NEXLIZET — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Oct 2024 LIPTRUZET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Aug 2024 ROSZET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Mar 2024 VYTORIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Feb 2024 ZETIA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Ezetimibe
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.